Volume 19 Issue 10
Oct.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(10): 1689-1692
FENG Min, LUO Bing. Clinical observation of different doses of pulmonary surfactant combined with INSURE technology in the treatment of neonatal respiratory distress syndrome[J]. Chinese Journal of General Practice, 2021, 19(10): 1689-1692. doi: 10.16766/j.cnki.issn.1674-4152.002143
Citation: FENG Min, LUO Bing. Clinical observation of different doses of pulmonary surfactant combined with INSURE technology in the treatment of neonatal respiratory distress syndrome[J]. Chinese Journal of General Practice, 2021, 19(10): 1689-1692. doi: 10.16766/j.cnki.issn.1674-4152.002143
shu

Clinical observation of different doses of pulmonary surfactant combined with INSURE technology in the treatment of neonatal respiratory distress syndrome

doi: 10.16766/j.cnki.issn.1674-4152.002143
  • 1.

    Department of Pediatrics, Anhui No.2 Provincial People's Hospital, Hefei, Anhui 230000, China

Funds:

 KJ2019A1099

  • Received Date: 2020-10-30
    Available Online: 2022-02-15
    Abstract
  •   Objective  To investigate the clinical effect of different doses of pulmonary surfactant (PS) combined with INSURE technology in the treatment of neonatal respiratory distress syndrome.  Methods  A total of 80 neonatal respiratory distress syndrome cases in the NICU of Anhui No.2 Provincial People's Hospital from January 2017 to September 2020 were selected as the research objects. According to the random number method, the children were divided into two groups with 40 cases in each group. Both groups were treated with INSURE technology and injected with PS. The control group was given 70 mg/kg PS, and the experimental group was given 100 mg/kg PS. The clinical efficacy, blood gas analysis index, oxygenation index, oxygen duration, length of hospital stay and incidence of complications of the two groups were compared before and after treatment.  Results  The total effective rate of the experimental group (100.0%) was higher than that of the control group (85.0%), and the difference was statistically significant (P < 0.05). The duration of oxygen use in the experimental group was significantly shorter than that of the control group (P < 0.05). No difference was observed in the length of stay between the two groups (P>0.05). No significant difference was observed in blood gas analysis and oxygenation indices between both groups before treatment (P>0.05). The blood gas analysis and oxygenation index after treatment were significantly improved compared with those before treatment; that is, PaO2 increased, PaCO2 decreased, and pH improved (all P < 0.05). The PaO2 [(77.55±5.79) mm Hg] of the experimental group was significantly higher than that of the control group [(72.45±4.37) mm Hg], whilst the PaCO2 [(39.45±2.45) mm Hg] was lower than that of the control group [(40.88±2.32) mm Hg]. The pH of the experimental group (7.36±0.02) was significantly better than that of the control group (7.35±0.02), with statistically significant differences (P < 0.05). The complication rate of the experimental group (12.5%) was lower than that of the control group (35.0%), and the difference was statistically significant (P < 0.05).  Conclusion  The treatment of neonatal respiratory distress syndrome with 100 mg/kg PS combined with INSURE technology can significantly improve the clinical symptoms, improve oxygenation and reduce the duration of oxygen use and clinical complications.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    MUSSAVI M, MIRNIA K, ASADOLLAHI K. Comparison of the efficacy of three natural surfactants (curosurf, survanta, and alveofact) in the treatment of respiratory distress syndrome among neonates: A Randomized Controlled Trial[J]. Iran J Pediatr, 2016, 26(5): e5743. http://pubmedcentralcanada.ca/pmcc/articles/PMC5297380/?lang=fr
    [2]
    黄方, 刘小辉. 肺泡表面活性物质联合双水平正压通气治疗新生儿呼吸窘迫综合征的疗效观察[J]. 临床肺科杂志, 2019, 24(6): 1023-1025. doi: 10.3969/j.issn.1009-6663.2019.06.015
    [3]
    叶玲. 不同的肺表面活性物质联合无创高频振荡通气治疗新生儿呼吸窘迫综合征的疗效对比[J]. 中国疗养医学, 2020, 29(11): 1203-1205. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGLX202011034.htm
    [4]
    肖小芳, 彭好. 肺表面活性物质在新生儿呼吸窘迫综合征的应用[J]. 医学综述, 2020, 26(7): 1379-1383. doi: 10.3969/j.issn.1006-2084.2020.07.026
    [5]
    SWEET D G, CARNIELLI V, GREISEN G, et al. European consensus guidelines on the management of respiratory distress syndrome -2019 update[J]. Neonatology, 2019, 115(4): 432-450. doi: 10.1159/000499361
    [6]
    王刚, 高敏. INSURE技术治疗早产儿呼吸窘迫综合征临床观察[J]. 中国临床新医学, 2017, 10(10): 978-981. doi: 10.3969/j.issn.1674-3806.2017.10.15
    [7]
    SARDESAI S, BINIWALE M, WERTHEIMER F, et al. Evolution of surfactant therapy for respiratory distress syndrome: Past, present, and future[J]. Pediatr Res, 2017, 81(1-2): 240-248. doi: 10.1038/pr.2016.203
    [8]
    CHUN J, SUNG S I, HO Y H, et al. Prophylactic versus early rescue surfactant treatment in preterm infants born at less than 30 weeks gestation or with birth weight less than or equal 1, 250 grams[J]. J Korean Med Sci, 2017, 32(8): 1288-1294. doi: 10.3346/jkms.2017.32.8.1288
    [9]
    李科纯, 钱素云, 曾健生. 肺表面活性物质治疗急性呼吸窘迫综合征研究现状[J]. 中国实用儿科杂志, 2018, 33(6): 431-434. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK201806010.htm
    [10]
    钱文亚, 谢晓恬. 外源性肺表面活性物质治疗新生儿呼吸窘迫综合征临床方法学研究[J]. 世界临床药物, 2020, 41(3): 177-182. https://www.cnki.com.cn/Article/CJFDTOTAL-GWHH202003006.htm
    [11]
    邵肖梅, 叶鸿瑁, 丘小汕. 实用新生儿学[M]. 5版. 北京: 人民卫生出版社, 2019: 575-578.
    [12]
    吴淑明, 郭淑艳, 赵旭. 肺表面活性物质联合持续气道正压通气治疗新生儿呼吸窘迫综合征的效果研究[J]. 中国妇幼保健, 2017, 32(17): 4174-4176. https://www.cnki.com.cn/Article/CJFDTOTAL-ZFYB201717053.htm
    [13]
    MEHRABADI A, LISONKOVA S, JOSEPH KS. Heterogeneity of respiratory distress syndrome: Risk factors and morbidity associated with early and late gestation disease[J]. BMC Pregnancy and Childbirth, 2016, 16(1): 281. doi: 10.1186/s12884-016-1085-7
    [14]
    张纪伟. 肺表面活性物质治疗新生儿呼吸窘迫综合征的临床疗效分析[J]. 临床医学, 2017, 37(3): 113-114. https://www.cnki.com.cn/Article/CJFDTOTAL-EBED201703052.htm
    [15]
    李凌, 张志红, 张慧琴, 等. 持续气道正压呼吸联合珂立苏治疗新生儿呼吸窘迫综合征的疗效观察[J]. 中南医学科学杂志, 2017, 45(5): 499-502. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYY201705018.htm
    [16]
    孔祥永, 封志纯, 杨慧霞, 等. 早产儿呼吸窘迫综合征早期防治专家共识[J]. 中华围产医学杂志, 2017, 20(8): 557-559. doi: 10.3760/cma.j.issn.1007-9408.2017.08.002
    [17]
    霍梦月, 梅花, 张钰恒, 等. 低侵入性肺表面活性物质治疗技术治疗新生儿呼吸窘迫综合征有效性和安全性的Meta分析[J]. 中国当代儿科杂志, 2020, 22(7): 721-727. https://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ202007011.htm
    [18]
    SWEET D G, CARNIELLI V, GREISEN G, et al. European consensus guidelines on the management of respiratory distress Syndrome -2016 update[J]. Neonatology, 2017, 111(2): 107-125. doi: 10.1159/000448985
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (180) PDF downloads(9) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return